VLS Valneva SE

VALNEVA Declaration of shares and voting rights: December 31, 2024

VALNEVA Declaration of shares and voting rights: December 31, 2024

VALNEVA

Declaration of shares and voting rights

December 31, 2024

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: January 3, 2025

Number of shares

composing the share capital of Valneva		Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**






162,521,524









ordinary shares with a par value of €0.15 each		178,404,975





Transfer into bearer form of 300 shares with double voting rights









Sale of 150 shares with double voting rights









Definitive attribution of 27,521 free ordinary shares









Double voting rights granted on 6,177 ordinary shares





December 2, 2024









December 5, 2024









December 6, 2024









Between December 1 & 28, 2024		178,280,653

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
03/01/2025

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Oscar Haffen Lamm
  • Oscar Haffen Lamm
VLS VALNEVA SE

Valneva: additional positive data for Ixchiq in adolescents

Valneva reported additional positive phase 3 data for its single-shot Ixchiq vaccine (CHIKV) in adolescents (aged 12-17 y.o), which showed a sustained 98.3% sero-response rate 12 months after a single vaccination in the subset of patients who were CHIKV negative at baseline, which further confirms

23h / 5m 23h / 5m 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Reports High Sustained Immune Response in Adolescents One Year...

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine Saint-Herblain (France), January 20, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination. These results support and strengthen the pivotal data previously reported for adolescents (12 to 17 years old) which supported filing for potential labe...

January 20, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva to Meet with Investors during the J.P. Morgan Healthcare Confe...

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference Saint Herblain (France), January 6, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 43nd Annual J.P. Morgan Healthcare Conference, January 13-15, 2025 in San Francisco. Valneva’s CEO Thomas Lingelbach and CFO Peter Bühler will discuss the Company’s commercial portfolio of vaccines, which is expected to generate €160 -...

January 6, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

VALNEVA Declaration of shares and voting rights: December 31, 2024

VALNEVA Declaration of shares and voting rights: December 31, 2024 VALNEVA Declaration of shares and voting rights December 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: January 3, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal num...

January 3, 2025 1 EN
Bruno Bulic
  • Bruno Bulic
VLS VALNEVA SE

Valneva pushing Ixchiq in Asia

Valneva announced an exclusive license agreement with India-based Serum Institute of India (SII), for the supply of the Chikungunya vaccine Ixchiq in Asia, a partnering falling under the scope of the Coalition for Epidemic Preparedness Innovations (CEPI) for low-and-middle-income countries (LMICs)

12/19/24 December 19, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch